NY‐ESO‐1: review of an immunogenic tumor antigen

S Gnjatic, H Nishikawa, AA Jungbluth, AO Güre… - Advances in cancer …, 2006 - Elsevier
In the 9 years since its discovery, cancer‐testis antigen NY‐ESO‐1 has made one of the
fastest transitions from molecular, cellular, and immunological description to vaccine and
immunotherapy candidate, already tested in various formulations in more than 30 clinical
trials worldwide. Its main characteristic resides in its capacity to elicit spontaneous antibody
and T‐cell responses in a proportion of cancer patients. An overview of immunological
findings and immunotherapeutic approaches with NY‐ESO‐1, as well the role of regulation …